London Stock Exchange welcomes Sensyne Health Plc
Sensyne Health plc (the "Company"), a British healthcare technology company focused on using clinical artificial intelligence to improve patient care and accelerate the development of new medicines in collaboration with NHS Trust partners, has today been admitted onto AIM, a market of the London Stock Exchange, under the ticker SENS.
Based on a Placing Price of 175 pence per Ordinary Share, the Company raised £60 million and had a market capitalisation of £225 million on admission.
Sensyne Health creates value through the analysis and commercialisation of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced and all analyses are subject to appropriate ethical oversight and information governance, including conformance with the NHS guidelines, UK data protection law and applicable regulatory guidance.
The Company analyses anonymised patient data in collaboration with NHS Trust partners Oxford University Hospitals NHS Foundation Trust ("OUH NHS Foundation Trust"), South Warwickshire NHS Foundation Trust and Chelsea and Westminster Hospital NHS Foundation Trust using proprietary clinical artificial intelligence algorithms developed by researchers at the University of Oxford and OUH NHS Foundation Trust and exclusively licensed to the Company.
From these analyses, the Company seeks to discover new insights that improve patient care and are of significant value to pharmaceutical companies throughout the research, development and commercialisation process for medicines. These insights lead to the creation of new intellectual property that may be licensed to pharmaceutical companies in return for upfront payments, milestone payments and royalties. Financial returns generated through the commercialisation of these insights are shared with the Company's NHS Trust partners via equity ownership in the Company and a share of royalties. No data are sold nor is any ownership or control of data transferred to the Company or its pharmaceutical collaborators during this process.
The Company also has a portfolio of clinically-validated, digital health software products currently being adopted by multiple NHS Trusts. Sensyne Health has lead discovery programmes in the following four broad therapeutic areas: (i) respiratory diseases, (ii) cardiovascular diseases, (iii) neurological diseases and (iv) immunological diseases and cancer.
Peel Hunt acted as Bookrunner in connection with the Placing and Nominated Adviser and Broker to the Company.
Lord (Paul) Drayson, CEO of Sensyne Health, commented:
"We are delighted to be joining the AIM market of the LSE and to being a listed company. Given our partnerships with NHS Trusts it was a natural choice to be listed in London. The support from institutional investors to our IPO has been excellent and provides us with the resources we need to grow our team of data scientists and clinicians in Oxford and London to help ensure that the full potential of AI powered analysis of anonymised NHS data is realised, providing benefits to patients and a financial return to the NHS."